Guest Editor(s)

• Dr. Godefridus J. (Frits) Peters

  Amsterdam UMC, location VUMC, Laboratory Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.

  Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.

  Website | E-mail

• Dr. Elisa Giovannetti

  Lab Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

  Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy.

  Website | E-mail

• Dr. Joseph Ciccolini

  Laboratoire de Pharmacocinétique et Toxicologie, CHU Timone, APHM, Marseille, France.

  SMARTc unit, Centre de Recherche en Cancérologie de Marseille, Marseille, France.

  Website | E-mail

Special Issue Introduction

Cancer Drug Resistance is cooperating with the 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC) - Pharmacology and Molecular Mechanisms (PAMM) Group (https://www.pamm2022.com/) and launching a Special Conference Issue. The 43rd EORTC - PAMM (December 15-17, 2022 in Florence, Italy) mainly focuses on innovation and application of pharmacological knowledge to cancer drug discovery and development, with particular attention to novel drugs and their mechanisms of action/resistance, pharmacometrics, and clinical application in oncology. The Special Issue will focus on a selection of papers from the conference to cover advances in cancer drug resistance.

Keywords

Cancer drug discovery, mechanisms of action of novel drugs, drug resistance

Submission Deadline

30 Apr 2023

Submission Information

For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR221103
Submission Deadline: 30 Apr 2023
Contacts: Susan Song, Managing Editor, susan@cdrjournal.com